PennyStock101

Second Sight Medical Products On Watchlist

NASDAQ:EYES   SECOND SIGHT MEDICAL PRODUCTS INC
On strong watch for a strong breakout above $.94 alert set for possible long entry
Short interest high at 11%
Earnings call transcript
Thank you, Lisa. Good afternoon, everyone and thank you for joining our call today. Today I’ll share updates on the current status of the patients and our early feasibility study. Our engagement with the FDA as we progressed toward a pivotal trial, the various research and development programs underway for future enhancements to the Orion user experience and the reimbursement landscape for Orion.

We continue to make good progress building out our Orion platform on all fronts and remain focused on advancing our clinical and research and development program. During this quarter, we completed another pre-submission to the FDA as part of the Breakthrough Devices Program and we have had ongoing discussions with the agent to reach consensus on the design of the pivotal trial for Orion.

Let me begin with a brief update on our early feasibility study, which as many of you know is being conducted in the US at the Ronald Reagan UCLA Medical Center in Los Angeles and at the Baylor College of Medicine in Houston. In October, we shared additional positive data from the early feasibility study at a number of important conferences and scientific forums including the American Academy of Ophthalmology, the Congress of Neurologic Surgeons and the Society for Neuroscience. These presentations have been very well received and there’s growing interest by key opinion leaders in the scientific community and Orion’s ability to provide useful, artificial vision to profoundly blind individuals including those blind from retinitis pigmentosa, diabetic retinopathy, glaucoma, optic nerve disease and eye injury.



Second Sight Medical Products, Inc. engages in the development, manufacture, and marketing of implantable visual prosthetics. Its product, the Argus II Retinal Prosthesis System, treats outer retinal degenerations, such as retinitis pigmentosa, also referred to as RP . The company was founded by Alfred E. Mann, Aaron Mendelsohn, Sam Williams, Robert J. Greenberg, and Gunnar Bjorg in 1998 and is headquartered in Sylmar, CA.
Your Intro To Penny Stock Trading Success...

Sign Up for our 100% Free Email Newsletter:
http://www.PennyStock101.org

Text Message Alerts ---> text 'PS101' to 67076
(It's FREE, however Msg&Data rates may apply.)
Home Stock Screener Forex Screener Crypto Screener Economic Calendar Shows How It Works Chart Features Pricing House Rules Moderators Website & Broker Solutions Widgets Charting Solutions Lightweight Charting Library Help Center Refer a friend Feature Request Blog & News Twitter
Profile Profile Settings Account and Billing Refer a friend My Support Tickets Help Center Ideas Published Followers Following Private Messages Chat Sign Out